跳至主要内容
临床试验/NCT06121011
NCT06121011招募中不适用

A Global Prospective Observational Registry of Patients With Pompe Disease

Amicus Therapeutics81 个研究点 分布在 12 个国家目标入组 500 人开始时间: 2024年2月16日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
招募中
入组人数
500
试验地点
81
主要终点
Evaluate long-term safety of Pompe disease treatments

研究概览

简要总结

This is a global, multicenter, prospective, observational registry of patients with Pompe disease, including those with late-onset pompe disease (LOPD) and infantile-onset pompe disease (IOPD). Both untreated patients and those being treated with an approved therapy for Pompe disease are eligible to participate.

The objectives of the registry are:

  • To evaluate the long-term safety of Pompe disease treatments through collection of data that describe the frequency of adverse events (AEs)/serious adverse events (SAEs) occurring in Pompe disease patients
  • To evaluate the long-term real-world effectiveness of Pompe disease treatments
  • To evaluate the long-term real-world impact of Pompe disease treatments on quality of life (QOL) and patient-reported outcomes (PROs)
  • To describe the natural history of untreated Pompe disease

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Diagnosis of LOPD or IOPD based on documented deficiency of GAA enzyme activity and/or GAA genotyping

排除标准

  • Patients who are currently receiving investigational therapy for Pompe disease in a clinical trial, a compassionate use program, or an expanded access program (EAP)

研究组 & 干预措施

Untreated patients (those who are not currently receiving any medical therapy for Pompe disease)

干预措施: Untreated (Other)

Cipaglucosidase alfa/Miglustat-treated patients

干预措施: Cipaglucosidase alfa (Biological)

Cipaglucosidase alfa/Miglustat-treated patients

干预措施: Miglustat (Drug)

Other Enyzme Replacement Therapy (ERT)-treated patients

干预措施: Alglucosidase alfa or Avalglucosidase alfa (Biological)

结局指标

主要结局

Evaluate long-term safety of Pompe disease treatments

时间窗: 5 years

Data collection that describe the frequency of AEs/SAEs occurring in Pompe disease patients

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (81)

Loading locations...

相似试验

A Global Prospective Observational Registry of... | 临床试验